未经证实:高血压是心血管疾病发病率和死亡率的最重要危险因素。在高收入国家诊断为高血压的患者中,血压控制率低至17%至31%;在中低收入国家中,控制率可能较差。在高收入国家诊断为高血压的患者中,血压控制率低至17%至31%;在中低收入国家中,控制率可能较差。总的来说,43%至66%的患者未能坚持其处方的抗高血压药物,一年后,约40%的高血压患者可能停止初始药物治疗。
未经评估:本研究的目的是评估单药联合降压药对治疗依从性的影响,血压控制和心血管事件vs.自由组合疗法。
未经评估:我们招募了192名年龄不超过79岁的成人高血压患者,尽管以前接受过免费的联合抗高血压治疗,但未经治疗或未控制的高血压,2020年11月至2022年3月。将接受单一药丸组合(SPC)治疗的患者与相同大小的手臂(n=96)进行比较,并根据接受标准自由组合(FC)抗高血压治疗的年龄和性别进行匹配。
UNASSIGNED:与SPC组相比,从基线到随访第6个月,办公室SBP显着降低FC组减少(21.9vs.13.1mmHg;p<0.0001)。SPC组的办公室DBP从基线到随访的第6个月明显减少,而免费联合治疗组(13.7vs.8.0mmHg;p<0.0001)。6个月时,94名参与者(98%)仍接受SPC治疗。在最后6个月的研究访问中,SPC治疗组中84.2%的患者坚持规定的抗高血压治疗与52%的患者在FC组。目标BP值(平均24h动态收缩压/舒张压<130/80mmHg)的SPC受者比自由组合治疗(78.2%vs.46.3%,p<0.05)在随访的第6个月。
未经证实:单药组合(SPC)治疗,是安全的新兴最佳实践,有效,快速,和方便的高血压控制。它提高了负担能力,动脉高血压的依从性和控制。
UNASSIGNED: Hypertension is the most important risk factor for cardiovascular morbidity and mortality. Blood pressure control rates are as low as 17% to 31% in patients diagnosed with hypertension in high-income countries; control rates are likely poorer in low- to middle- and low-income countries. Blood pressure control rates are as low as 17% to 31% in patients diagnosed with hypertension in high-income countries; control rates are likely poorer in low- to middle- and low- income countries. Overall, 43% to 66% of patients fail to adhere to their prescribed antihypertensive medications, and after 1 year, ≈40% of patients with hypertension may stop their initial drug treatment.
UNASSIGNED: The aim of the study was to evaluate the effects of single pill combination antihypertensive drugs on the adherence to treatment, blood pressure control and cardiovascular events vs. free-combination therapy.
UNASSIGNED: We enrolled 192 adult hypertensive patients not older than 79 years, with untreated or uncontrolled hypertension despite previously receiving free combination antihypertensive therapy, between November 2020 and March 2022. Patients treated with single pill combination (SPC) were compared with an arm of the same size (n = 96) and matched by age and gender who received a standard free combination (FC) antihypertensive therapy.
UNASSIGNED: There were significant reductions from baseline to month 6 of follow-up in office SBP in the SPC group vs. reduction in FC group (21.9 vs. 13.1 mmHg; p < 0.0001). There were significant reductions from baseline to month 6 of follow-up in office DBP in the SPC group vs. group with free-combination therapy (13.7 vs. 8.0 mmHg; p < 0.0001). At 6 months, 94 participants (98%) were still prescribed the SPC therapy. At the final 6-month study visit, 84.2% of patients in the SPC therapy group were adherent to the prescribed antihypertensive therapy vs. 52% of patients in the FC group. Target BP values (mean 24h ambulatory systolic/diastolic BP < 130/80 mmHg) were reached by more recipients of SPC than free-combination therapy (78.2% vs. 46.3%, p < 0.05) at month 6 of follow-up.
UNASSIGNED: Treatment with single pill combinations (SPC), is the emerging best practice for safe, effective, rapid, and convenient hypertension control. It improves the affordability, adherence and control of arterial hypertension.